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thyroid cancer expert including Nuclear Medicine Phy-
sicians and Endocrinologists to provide a consensus on 
the post-surgical ablation in thyroid cancer patients. The 
task force had no conflict of interest and had no commer-
cial support. A number of specific topics were selected 
and the members selected relevant papers by searching in 
the Pubmed for articles published from 2000 to January 
2015. Selected studies were categorized by level of evi-
dence, and the recommendations were graded according 
to the level of evidence as high (A), moderate (B), or low 
(C).
Keywords Radioiodine · Thyroid ablation · Thyroid 
cancer · Thyroglobulin · rhTSH
Introduction
Post-surgical ablation of thyroid remnant with radioactive 
iodine (RAI) (remnant ablation) in differentiated thyroid 
cancer (DTC) is aimed to facilitate the early detection of 
recurrence based on serum thyroglobulin (Tg) measure-
ment and/or RAI whole-body scan (WBS) and to obtain 
a post-therapy WBS, whose results may change the initial 
staging by identifying previously undiagnosed disease. In 
addition, RAI ablation may represent an adjuvant therapy 
by cleaning persistent microscopic foci of cancer which 
can be present in the thyroid remnant especially in papil-
lary thyroid cancer (PTC) that are frequently multifocal. 
While the first aim, remnant ablation, is related to follow-
up in any patient regardless of his specific risk, the second 
one, adjuvant therapy, is advocated as a tool to reduce the 
rates of disease recurrence or cause-specific mortality [1], 
and thus its use must be justified according to a real risk 
of recurrence. Indeed, in patients at the lowest risk for 
Abstract Post-surgical ablation of thyroid  remnant with 
radioactive iodine (RAI) in differentiated thyroid cancer 
(DTC) is aimed to destroy any thyroid remnant in the thy-
roid bed (remnant ablation) and any microscopic foci of 
cancer cells eventually present within the thyroid remnant 
(adjuvant therapy). The present text is an attempt to offer 
practice guidelines for the indication of thyroid ablation 
and the preparation of DTC patients considering the latest 
achievement in the field and the changing epidemiology of 
DTC observed in the last 10 years.
Methodology The executive committee of the Ital-
ian Society of Endocrinology appointed a task force of 
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recurrence and mortality several studies have shown no 
benefit of remnant ablation [2]. Benefit becomes evident 
in patients considered at intermediate [3] or high risk, par-
ticularly in terms of reduced recurrence rate and possibly of 
reduced mortality.
Based on this consideration, several authoritative guide-
lines have restricted the indication for RAI ablation to spe-
cific categories of patients considered at significant risk of 
recurrence or death. Since selection of patients for thyroid 
ablation is not the aim of this guideline, we refer to them 
for further reading.
Here we will limit our discussion to the choice of the 
most appropriate activity of 131I (low or high) to be used 
whenever thyroid ablation has been decided, including the 
definition of successful thyroid ablation and the method of 
preparation for RAI administration.
Definition of successful remnant ablation
In the past, successful remnant ablation was defined as the 
absence of visible RAI uptake on a diagnostic RAI WBS 
performed 6–12 months after remnant ablation. With the 
introduction of serum Tg measurement and neck ultra-
sound in clinical practice, the use of performing diagnostic 
WBS has been largely abandoned. Indeed, both serum Tg 
determination [4–8] and neck sonography examination [9] 
are much more sensitive compared to diagnostic WBS in 
detecting the existence of persistent or recurrent disease 
[4–8]. Nowadays, the most accepted definition of success-
ful thyroid ablation is an undetectable stimulated serum 
Tg (or an undetectable basal serum Tg if using ultra-
sensitive Tg assays) combined with undetectable serum 
anti-thyroglobulin antibodies (TgAb) and a negative neck 
ultrasound.
TgAb are commonly identified in patients with differ-
entiated follicular cell-derived thyroid cancer. Their fre-
quency in patients with DTC is approximately 20–25 % 
[10]. In case of positive TgAb, serum Tg cannot be use as 
a predictor of ablation and we have to rely on neck ultra-
sound and on the trend of serum TgAb. A diagnostic WBS 
may be considered in this setting. Antibody levels may 
serve as a surrogate biochemical marker of disease per-
sistence and response to therapy. However, the timing of 
testing and the duration to see a maximal response appear 
to differ from Tg levels in patients without TgAb. There 
may be an initial transient rise in TgAb titer after radioac-
tive iodine (RAI) treatment [11]. Also, it has been shown 
that the eventual disappearance of TgAb takes approxi-
mately 2–3 years on average. Complete ablation of thy-
roid tissue with its antigenic components results in the 
disappearance of antibodies to all major thyroid antigens 
[10–12].
Preparation for RAI ablation
Remnant ablation has been traditionally performed after 
thyroid hormone withdrawal to increase endogenous thy-
roid-stimulating hormone (TSH) to levels sufficient to 
induce robust RAI uptake in thyroid cells. Empirically, it 
is estimated that a TSH of >30 mU/L is a good cut off [13], 
but no comparative study has ever been done to document 
this assumption.
For thyroid hormone withdrawal, two possible 
approaches are used: switch from levothyroxine (LT4) to 
triiodothyronine (LT3) for some weeks [5, 6] and then stop 
LT3 for 2 weeks, or stop LT4 for 3–4 weeks without switch-
ing to LT3. These two methods have not been compared in 
terms of better outcomes of ablation.
Since several years, the alternative way of preparation 
for RAI ablation is the administration of exogenous recom-
binant human TSH (rhTSH), after a prospective, multi-
center, randomized study demonstrated that 131I remnant 
ablation with 100 mCi was equally effective after rhTSH 
stimulation or thyroid hormone withdrawal [14]. In another 
study, ablation rates were similar with either withdrawal or 
preparation with rhTSH using 50 mCi of 131I [15]. Addi-
tional evidence that preparation with thyroid hormone 
withdrawal or rhTSH has the same ablation outcome using 
both high or low radioiodine doses has been provided in 
two prospective randomized multicenter studies, one in 
France and one in the UK [16, 17]. In addition, short-term 
recurrence rates have been found to be similar in patients 
prepared with thyroid hormone withdrawal or rhTSH [18, 
19]. The preparation with rhTSH significantly improves 
quality of life [14, 20], and reduces both whole-body irradi-
ation [21, 22] and hospitalization time [23]. A recent meta-
nalysis confirms the above results [24]. Nowadays, the use 
of rhTSH is approved for remnant ablation, with any 131I 
dose, both in the United States and Europe.
Recommendation 1
Patients undergoing RAI ablation should be preferentially 
prepared by rhTSH administration. Thyroid hormone with-
drawal may be considered whenever rhTSH is not available 
or not affordable. Recommendation rating: A.
Which is the best activity of 131I to be employed 
for post‑surgical thyroid remnant ablation
Although there is a trend toward higher ablation rates with 
higher activities [25, 26], activities between 30 and 100 mCi 
of 131I generally show similar rates of successful remnant 
ablation [27–30]. A randomized study using preparation 
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with rhTSH showed that ablation rates were comparable 
with 50 mCi compared to 100 mCi [31]. A prospective, 
randomized study performed in 160 patients, comparing 
ablation with 30 and 100 mCi, after preparation with thy-
roid hormone withdrawal, found no difference in both the 
ablation rate and in the rate or recurrence during follow-up 
[32]. Recently, two prospective randomized studies in very 
large number of patients conducted in France and in the 
United Kingdom found no significant difference in the rem-
nant ablation rate using 30 or 100 mCi of 131I, either after 
preparation with thyroid hormone withdrawal or rhTSH [16, 
17]. It is worth noting, that these two studies included not 
only low-risk patients, but also patients at intermediate risk 
of recurrence, including those showing minimal extrathy-
roidal extension of the primary tumor [17] or lymph node 
metastases [16, 17]. Also in this category the authors found 
no difference between low- and high-RAI doses in terms of 
ablation success rates. This finding has been confirmed in 
a retrospective study including only patients at intermedi-
ate risk, treated with low- or high-RAI activities [33]. In this 
study, the authors were also able to demonstrate that, with 
regard to recurrences or deaths, the long-term outcome was 
not affected by the ablation dose (low or high). Concerning 
the issue of the follow-up of patients treated with low activ-
ity of 131-I and rhTSH or LT4 withdrawal, a recent study 
[19] showed that in 10 years of follow-up, the rate of recur-
rence was as low as expected (3.5 %) and similar in both 
groups. Moreover, the final outcome of these patients was 
similar at the end of follow-up (Table 1).
No definite studies are available in pediatric patients. 
For every age patients, some authors have suggested to use 
a lesion dosimetry or to give the highest dose administra-
ble based on the radiation exposure to the critical organs at 
risk, especially in high-risk group; others suggest empiric 
dosage and others an activity based on the patient’s body 
weight [34–37].
Recommendation 2
The minimum activity (30 mCi) necessary to achieve suc-
cessful remnant ablation should be utilized, particularly in 
patients at low risk and intermediate risk. Recommendation 
rating: B.
Recommendation 3
In patients considered at high risk for recurrence, or if 
residual microscopic disease is suspected or documented, 
higher activities (100 mCi or more) should be considered. 
Recommendation rating: C.
In such patients at high risk, some authors have advo-
cated the use of 124I PET as a better diagnostic proce-
dure compared to 131I whole-body scanning in staging 
disease burden. Relative to 131I planar whole-body imag-
ing, 124I PET identified as many as 50 % more foci of 
radioiodine uptake suggestive of additional residual thy-
roid tissue and/or metastases in as many as 32 % more 
patients [38]. Thus, when available, a 124I PET/CT could 
be used to perform dosimetry, to tailor treatment, instead 
of using fixed activities, and to evaluate mean absorbed 
Table 1  Guidelines for radioiodine thyroid ablation
Recommendation Rating
Preparation for RAI ablation 1. Patients undergoing RAI ablation should be preferentially prepared by  
rhTSH administration [14, 16, 17]
A
Which is the best activity of 131I to be employed  
for post-surgical thyroid remnant ablation
2. The minimum activity (30 mCi) necessary to achieve successful remnant  
ablation should be utilized, particularly in patients at low risk and  
intermediate risk [31–33]
B
3. In patients considered at high risk for recurrence, or if residual microscopic 
disease is suspected or documented, higher activities (100 mCi or more)  
should be considered [40]
C
Diagnostic RAI scanning before ablation 4. Pre-ablation diagnostic scans are seldom informative as far as the decision  
to ablate is concerned. They may be considered when a sustained suspicion of 
local or distant metastases is present to better define the activity of RAI to be 
administered or in patients with elevated levels of serum TgAb [38, 40–42]
C
Post-operative serum Tg levels and neck US 5. Post-operative serum Tg levels (in the absence of serum TgAb) and neck  
US may give additional information regarding the need for ablation and  
the radioiodine dose to be administered [47, 48]
C
Is a low-iodine diet necessary before  
remnant ablation?
6. At least in countries with mild or moderate iodine deficiency, there is no  
need to prescribe a low-iodine diet before remnant ablation. Avoidance  
of iodine-containing drugs or contrast agents is mandatory [53]
B
Post-therapy WBS after remnant ablation 7. A post-therapy WBS is recommended following remnant ablation. This is  
typically done 3–7 days after the therapeutic dose is administered [54, 55]
A
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doses both to target lesions and to non-target organs (sali-
vary glands).
Should a diagnostic RAI scanning be performed 
before ablation? Should post‑surgical serum  
Tg levels be considered in decision making?
A diagnostic RAI WBS provides information on the pres-
ence of iodine-avid thyroid tissue, which may represent the 
normal thyroid remnant or the presence of residual disease. 
There is an increasing trend to avoid diagnostic RAI scans 
because of its low impact on the decision to ablate, and 
because of concerns over 131I-induced stunning of normal 
thyroid remnants [39] and distant metastases from thyroid 
cancer [40–42]. The alternative radiopharmaceutical for 
staging, 123I, is not readily available and has a short half-
life. [43–45].
Recommendation 4
Pre-ablation diagnostic scans are seldom informative as far 
as the decision to ablate is concerned. They may be consid-
ered when a sustained suspicion of local or distant metas-
tases is present to better define the activity of RAI to be 
administered or in patients with elevated levels of serum 
TgAb. In any case, diagnostic scans should be performed 
using tracer doses of 123I (if available) or low 131I activity 
(1–2 mCi). In the last case, the therapeutic activity should 
be delivered within 72 h of the diagnostic activity to avoid 
stunning. Recommendation Rating: C.
Post‑operative serum Tg levels and neck US
Some studies investigating the clinical significance of post-
operative serum Tg levels have shown that low post-opera-
tive levels of non-stimulated Tg does not exclude persistent 
disease [46]. However, serum Tg levels may be useful for 
the indication of 131I activity to be delivered [47] and may 
represent a significant prognostic marker [48, 49].
Similar prospective information may be derived from 
the execution of neck US before ablation. US should be 
performed to check the central and lateral compartments 
of the neck whenever a cancer is fortuitously discovered at 
histology, or a preoperative US has not been done or in the 
presence of high pre-ablation serum Tg values.
Recommendation 5
Post-operative serum Tg levels (in the absence of serum 
TgAb), and neck US may give additional information 
regarding the need for ablation and the radioiodine dose to 
be administered. Recommendation Rating C.
Is a low‑iodine diet necessary before remnant ablation?
Contamination with stable iodine might theoretically 
influence the uptake of diagnostic or therapeutic doses 
of RAI [50–52]. Based on this assumption, several cent-
ers advocate preparation of the patients with a low-
iodine diet and recommend avoiding iodine contamina-
tion (intravenous contrast agents, amiodarone, or other 
iodine-containing drugs) prior to RAI therapy. However, 
no prospective study has ever determined the cut off at 
which interference may actually occur. In a retrospective 
study, aimed to compare different levels of urinary iodine 
excretion on the results of thyroid ablation in patients 
not prepared with low-iodine diet, the authors found 
no influence of different levels of urinary iodine on the 
outcome of thyroid ablation up to urinary iodine levels 
exceeding 350 µg/day of dietary iodine. In addition, the 
median level of iodine urinary content in Italy is as low 
as in mild iodine-deficient countries [53] and thus, there 
is no reason to limit the diet and the use of iodized salt in 
our country. In any case, measurement of urinary iodine 
excretion (when available) before remnant ablation may 
help in detecting the few cases with significant iodine 
contamination.
Recommendation 6
At least in countries with mild or moderate iodine defi-
ciency, there is no need to prescribe a low-iodine diet 
before remnant ablation. Avoidance of iodine-containing 
drugs or contrast agents is mandatory. If a suspicion of 
iodine contamination exists, iodine excretion should be 
evaluated starting from 20 to 30 days after the withdrawal 
of the iodine-containing drug or the contrast agent injec-
tion. Recommendation Rating: B.
Post‑therapy WBS after remnant ablation
It is recommended to perform a post-therapy WBS within 
1 week after RAI therapy. This imaging technique is of 
paramount importance in confirming the presence and the 
extent of the thyroid remnant and may disclose the pres-
ence of unsuspected metastatic foci in 10–26 % of the 
cases [55], thus allowing the reclassification of the disease 
stage [56]. Whenever possible, a SPECT-CT can be useful 
instead of a planar WBS to better define the neck uptake 
and distinguish the remnant from local lymph node or para-
tracheal tumor [57].
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Recommendation 7
A post-therapy WBS is recommended following RAI rem-
nant ablation. This is typically done 3–7 days after the ther-
apeutic dose is administered. Recommendation Rating: A.
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